Erickson Zachary D, Mena Shirley J, Pierre Joseph M, Blum Lisa H, Martin Eda, Hellemann Gerhard S, Aragaki Dixie R, Firestone Lisa, Lee Catherine, Lee Paul, Kunkel Charles F, Ames Donna
Research Department, VA Greater Los Angeles Healthcare System, Los Angeles, California.
J Clin Psychiatry. 2016 Feb;77(2):e183-9. doi: 10.4088/JCP.14m09552.
To demonstrate the effectiveness of a Diabetes Prevention Program-inspired 12-month behavioral intervention for patients with severe mental illness (SMI) and medication-associated obesity.
This randomized, controlled, parallel, superiority study screened 225 volunteers from November 2005 to August 2008 at the VA Greater Los Angeles Healthcare System. 122 outpatients with DSM-IV-diagnosed SMI taking antipsychotic medications who had ≥ 7% weight gain or body mass index (BMI) > 25 were randomized by computer-generated number to Lifestyle Balance treatment intervention (n = 60) or usual care control (n = 62) groups. Clinical raters were masked to randomization. Treatment intervention included weekly classes and individual counseling for 8 weeks, food and exercise diaries, rewards, caregiver consultations, and monthly booster classes and counseling for 1 year. Controls received self-help materials and visited at equivalent intervals without formal classes or counseling. Outcomes were changes in anthropometric measurements, psychiatric symptoms, health knowledge, and glucose, hemoglobin A1c, and lipid levels.
Our intention-to-treat analysis found significant differences in predicted trajectory of mean weight change between the groups over 12 months (P < .01), with treatment participants expected to lose an average 4.6 kg, while control participants would gain an average 0.6 kg. BMI and body fat percentage followed the same pattern. Both groups demonstrated statistically significant improvements in health knowledge quiz scores over time (P = .006), without significant difference between groups.
Treatment was more effective than usual care control in treating medication-associated obesity, independent of SMI diagnosis, antipsychotic medication, and knowledge gained, suggesting that behavioral interventions are effective in SMI patients.
ClinicalTrials.gov Identifier: NCT00344500.
证明一项受糖尿病预防计划启发的为期12个月的行为干预措施对重症精神疾病(SMI)和药物相关性肥胖患者的有效性。
这项随机、对照、平行、优效性研究于2005年11月至2008年8月在洛杉矶退伍军人事务部大医疗系统筛选了225名志愿者。122名诊断为DSM-IV标准的服用抗精神病药物且体重增加≥7%或体重指数(BMI)>25的门诊SMI患者通过计算机生成的数字随机分为生活方式平衡治疗干预组(n = 60)或常规护理对照组(n = 62)。临床评估者对随机分组情况不知情。治疗干预包括为期8周的每周课程和个体咨询、饮食和运动日记、奖励、照顾者咨询,以及为期1年的每月强化课程和咨询。对照组接受自助材料,并在相同间隔时间就诊,但没有正式课程或咨询。观察指标为人体测量指标、精神症状、健康知识以及血糖、糖化血红蛋白和血脂水平的变化。
我们的意向性分析发现,两组在12个月内平均体重变化的预测轨迹存在显著差异(P <.01),治疗组参与者预计平均减重4.6千克,而对照组参与者预计平均增重0.6千克。BMI和体脂百分比呈现相同模式。两组的健康知识测验分数随时间推移均有统计学意义的显著改善(P =.006),但组间无显著差异。
在治疗药物相关性肥胖方面,治疗比常规护理对照更有效,与SMI诊断、抗精神病药物以及所获知识无关,这表明行为干预对SMI患者有效。
ClinicalTrials.gov标识符:NCTxx00344500 。 (注:原文此处NCT00344500中xx为译者笔误,实际无此内容)